Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Suhr

Showing results (161-170 of 178) with videos related to

Pageof 18
Sort By:
Orphanet Journal of Rare Diseases|September 5, 2015
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose studyOle B Suhr, Teresa Coelho, Juan Buades, et al.
European Journal of Gastroenterology & Hepatology|January 4, 2021
Recommendations for the diagnosis and management of transthyretin amyloidosis with gastrointestinal manifestationsRadislav Nakov, Ole B Suhr, Gianluca Ianiro, et al.
Journal of Dermatological Science|March 31, 1999
Arginine in the beginning of the 1A rod domain of the keratin 10 gene is the hot spot for the mutation in epidermolytic hyperkeratosisJ M Yang, K Nam, S W Kim, et al.
Frontiers in Genetics|July 10, 2015
Future opportunities and trends for e-infrastructures and life sciences: going beyond the grid to enable life science data analysisAfonso M S Duarte, Fotis E Psomopoulos, Christophe Blanchet, et al.
Journal of the American Chemical Society|September 13, 2023
Well-Defined Iron Sites in Crystalline Carbon NitrideAlexandre Genoux, Magnus Pauly, Conor L Rooney, et al.
Orphanet Journal of Rare Diseases|July 10, 2020
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosisTeresa Coelho, David Adams, Isabel Conceição, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 16, 2011
The diflunisal trial: update on study drug tolerance and disease progressionJ L Berk, P J Dyck, L Obici, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 4, 2012
The Diflunisal Trial: study accrual and drug toleranceJohn L Berk, Ole B Suhr, Yoshiki Sekijima, et al.
Journal of Neurology|August 27, 2013
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathyTeresa Coelho, Luis F Maia, Ana Martins da Silva, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 30, 2013
Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosisElisabet Ihse, Claudio Rapezzi, Giampaolo Merlini, et al.
Pageof 18

Showing results (161-170 of 178) with videos related to

Sort By:
Pageof 18
Orphanet Journal of Rare Diseases|September 5, 2015
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose studyOle B Suhr, Teresa Coelho, Juan Buades, et al.
European Journal of Gastroenterology & Hepatology|January 4, 2021
Recommendations for the diagnosis and management of transthyretin amyloidosis with gastrointestinal manifestationsRadislav Nakov, Ole B Suhr, Gianluca Ianiro, et al.
Journal of Dermatological Science|March 31, 1999
Arginine in the beginning of the 1A rod domain of the keratin 10 gene is the hot spot for the mutation in epidermolytic hyperkeratosisJ M Yang, K Nam, S W Kim, et al.
Frontiers in Genetics|July 10, 2015
Future opportunities and trends for e-infrastructures and life sciences: going beyond the grid to enable life science data analysisAfonso M S Duarte, Fotis E Psomopoulos, Christophe Blanchet, et al.
Journal of the American Chemical Society|September 13, 2023
Well-Defined Iron Sites in Crystalline Carbon NitrideAlexandre Genoux, Magnus Pauly, Conor L Rooney, et al.
Orphanet Journal of Rare Diseases|July 10, 2020
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosisTeresa Coelho, David Adams, Isabel Conceição, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 16, 2011
The diflunisal trial: update on study drug tolerance and disease progressionJ L Berk, P J Dyck, L Obici, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 4, 2012
The Diflunisal Trial: study accrual and drug toleranceJohn L Berk, Ole B Suhr, Yoshiki Sekijima, et al.
Journal of Neurology|August 27, 2013
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathyTeresa Coelho, Luis F Maia, Ana Martins da Silva, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 30, 2013
Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosisElisabet Ihse, Claudio Rapezzi, Giampaolo Merlini, et al.
Pageof 18